MCID: ANP009
MIFTS: 44

Anaplastic Oligodendroglioma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Anaplastic Oligodendroglioma

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 53 59 55 73

Characteristics:

Orphanet epidemiological data:

59
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251630
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 74 C0334590
UMLS 73 C0334590

Summaries for Anaplastic Oligodendroglioma

MalaCards based summary : Anaplastic Oligodendroglioma is related to oligoastrocytoma and pilocytic astrocytoma, and has symptoms including headache and seizures. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Glioma and DNA Damage. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Anaplastic Oligodendroglioma

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 30.3 GFAP IDH2 MGMT
2 pilocytic astrocytoma 29.1 CDKN2A GFAP MGMT
3 medulloblastoma 28.4 EGFR GFAP MGMT
4 brain cancer 28.3 EGFR GFAP IDH2 MGMT
5 glioblastoma 28.2 CDKN2A EGFR IDH2 MGMT
6 glioma 28.0 CDKN2A EGFR IDH2 POT1
7 grade iii astrocytoma 27.0 CDKN2A EGFR GFAP IDH2 MGMT
8 oligodendroglioma 26.9 CDKN2A CDKN2C EGFR GFAP IDH2 MGMT
9 protoplasmic astrocytoma 10.4 GFAP IDH2
10 gemistocytic astrocytoma 10.4 GFAP IDH2
11 pleomorphic xanthoastrocytoma 10.3 GFAP MGMT
12 periosteal chondrosarcoma 10.2 CDKN2A IDH2
13 spinal cord astrocytoma 10.2 GFAP MGMT
14 astrocytoma 10.2
15 anal squamous cell carcinoma 10.2 CDKN2A MGMT
16 primary central nervous system lymphoma 10.2 CDKN2A MGMT
17 breast giant fibroadenoma 10.1 CDKN2A MGMT
18 atypical neurofibroma 10.1 CDKN2A GFAP
19 leukemia 10.1
20 arteriovenous malformation 10.1
21 necrotizing sialometaplasia 10.0 CDKN2A GFAP
22 central nervous system lymphoma 10.0 CDKN2A MGMT
23 juvenile pilocytic astrocytoma 10.0 CDKN2A GFAP
24 cerebritis 10.0
25 anaplastic oligoastrocytoma 10.0
26 brain stem glioma 10.0 EGFR IDH2
27 fibrillary astrocytoma 9.9 GFAP IDH2 MGMT
28 gliomatosis cerebri 9.8 EGFR GFAP
29 cerebral cavernous malformations 9.8
30 multiple sclerosis 9.8
31 williams-beuren syndrome 9.8
32 psoriatic arthritis 9.8
33 leukemia, acute lymphoblastic 9.8
34 acute leukemia 9.8
35 arthritis 9.8
36 hydrocephalus 9.8
37 lymphoma 9.8
38 lymphoblastic leukemia 9.8
39 central neurocytoma 9.8
40 gangliocytoma 9.8
41 lynch syndrome 9.8
42 mixed glioma 9.8
43 ganglioglioma 9.8
44 cerebral lymphoma 9.8
45 paraplegia 9.8
46 cerebellar liponeurocytoma 9.8
47 meningitis 9.8
48 thunderclap headache 9.8
49 cavernous malformation 9.8
50 headache 9.8

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

UMLS symptoms related to Anaplastic Oligodendroglioma:


headache, seizures

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.77 EGFR
2 Decreased viability GR00221-A-1 9.77 CDKN2C EGFR POT1 CDKN2A
3 Decreased viability GR00221-A-3 9.77 POT1 CDKN2A
4 Decreased viability GR00221-A-4 9.77 EGFR POT1 CDKN2A
5 Decreased viability GR00301-A 9.77 CDKN2C
6 Decreased viability GR00342-S-2 9.77 CDKN2C
7 Decreased viability GR00402-S-2 9.77 EGFR POT1 CDKN2A CDKN2C

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.55 IDH2 CDKN2A CDKN2C EGFR GFAP
2 neoplasm MP:0002006 9.35 MGMT CDKN2A CDKN2C EGFR IDH2
3 no phenotypic analysis MP:0003012 8.92 MGMT POT1 CDKN2A EGFR

Drugs & Therapeutics for Anaplastic Oligodendroglioma

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 319)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
6
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
7
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
10
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
13
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
14
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
15 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
16 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
18 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
19 Keratolytic Agents Phase 3,Phase 1,Phase 2
20 Antimitotic Agents Phase 3,Phase 1,Phase 2
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
23 Analgesics Phase 3,Phase 1,Phase 2
24 Adjuvants, Anesthesia Phase 3
25 Central Nervous System Stimulants Phase 3,Phase 2
26 Cholinergic Agents Phase 3,Phase 2
27 Cholinesterase Inhibitors Phase 3,Phase 2
28 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Narcotics Phase 3
30 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
31 Analgesics, Opioid Phase 3
32 Anesthetics Phase 3,Phase 1
33 Nootropic Agents Phase 3,Phase 2
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
37 Liver Extracts Phase 3,Phase 2,Phase 1
38 Dopamine Agents Phase 3,Not Applicable
39
Histamine Phosphate Phase 3 51-74-1 65513
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Histamine Antagonists Phase 3
43 Histamine H1 Antagonists Phase 3
44 Neurotransmitter Uptake Inhibitors Phase 3
45 Dexmethylphenidate Hydrochloride Phase 3
46 Anti-Allergic Agents Phase 3
47 Dopamine Uptake Inhibitors Phase 3
48 Antipruritics Phase 3
49 Cola Nutraceutical Phase 3,Phase 1
50
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 235)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
7 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
8 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
10 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
11 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
12 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
13 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
14 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
15 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
16 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
17 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
18 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
19 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
20 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
21 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
22 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
23 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
24 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
25 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
26 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2 Thalidomide
27 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
28 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
29 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide Completed NCT00369590 Phase 2
30 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
31 Fenretinide in Treating Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
32 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
33 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
34 Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
35 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
36 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
37 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
38 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed NCT00042991 Phase 1, Phase 2 gefitinib
39 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
40 Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma Completed NCT00087061 Phase 1, Phase 2 gimatecan
41 Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma Completed NCT00404248 Phase 1, Phase 2 terameprocol
42 Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
43 Temozolomide in Treating Patients With Recurrent High-Grade Glioma Completed NCT00619112 Phase 2 temozolomide
44 Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00005855 Phase 1, Phase 2 carmustine;efaproxiral
45 Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors Completed NCT00003574 Phase 2
46 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
47 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
48 EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Completed NCT00006093 Phase 1, Phase 2 cilengitide
49 COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00004147 Phase 1, Phase 2 incyclinide
50 Study of Capecitabine to Treat Recurrent High Grade Gliomas Completed NCT00717197 Phase 2 Capecitabine

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Genetic Tests for Anaplastic Oligodendroglioma

Anatomical Context for Anaplastic Oligodendroglioma

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

41
Brain, Bone, Bone Marrow, T Cells, Liver, Spinal Cord, Endothelial

Publications for Anaplastic Oligodendroglioma

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 127)
# Title Authors Year
1
A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. ( 29076897 )
2017
2
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
3
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
4
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. ( 28472509 )
2017
5
Multimodal (18)F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. ( 28844925 )
2017
6
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
7
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
8
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
9
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
10
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
11
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
12
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
13
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. ( 26167373 )
2015
14
Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. ( 26018682 )
2015
15
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( 25534576 )
2015
16
TCF12 is mutated in anaplastic oligodendroglioma. ( 26068201 )
2015
17
A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12. ( 26341368 )
2015
18
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. ( 26354927 )
2015
19
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. ( 26352098 )
2015
20
A case of mushroom-shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging. ( 26622514 )
2015
21
Increased 99mTc TRODAT-1 Uptake in Anaplastic Oligodendroglioma. ( 23603602 )
2014
22
Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. ( 24447608 )
2014
23
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
24
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
25
Novel MSH6 mutations in treatment-naA^ve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( 25078279 )
2014
26
Cavernous angioma within the context of anaplastic oligodendroglioma: case report and review of the literature. ( 24844794 )
2014
27
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
28
Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion. ( 23711170 )
2014
29
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
30
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. ( 23527265 )
2013
31
Differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma: a case report of an elderly man. ( 23979650 )
2013
32
Anaplastic oligodendroglioma in an adolescent with Lynch syndrome. ( 23255519 )
2013
33
Leukemia-like onset of bone marrow metastasis from anaplastic oligodendroglioma after 17A years of dormancy: an autopsy case report. ( 23900511 )
2013
34
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. ( 23071247 )
2013
35
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
36
Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. ( 24527191 )
2013
37
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. ( 23907441 )
2013
38
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
39
Feline anaplastic oligodendroglioma: long-term remission through radiation therapy and chemotherapy. ( 23651604 )
2013
40
Pitfalls of conservative treatments of multiple probable cerebral cavernous malformations (CCMs): clinicopathological features of CCMs coexisting with vasculogenic mimicry in an anaplastic oligodendroglioma. ( 24337536 )
2013
41
Extraneural metastases of anaplastic oligodendroglioma. ( 24373094 )
2013
42
Minding the Ps and Qs: perseverance and quality studies lead to major advances in patients with anaplastic oligodendroglioma. ( 23071223 )
2013
43
Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. ( 25054579 )
2013
44
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( 23071237 )
2013
45
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. ( 23681562 )
2013
46
Anaplastic oligodendroglioma: advances and treatment options. ( 23344797 )
2013
47
Paraplegia due to drop metastases from anaplastic oligodendroglioma. ( 21591854 )
2012
48
Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. ( 23243547 )
2012
49
Long-term survival in a dog with anaplastic oligodendroglioma treated with radiation therapy and CCNU. ( 22785244 )
2012
50
Anaplastic oligodendroglioma involving the subcutaneous tissue of the scalp: report of an exceptional case and review of the literature. ( 22157246 )
2012

Variations for Anaplastic Oligodendroglioma

Expression for Anaplastic Oligodendroglioma

Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.

Pathways for Anaplastic Oligodendroglioma

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.25 CDKN2A CDKN2C EGFR
2 11.8 CDKN2A CDKN2C MGMT
3 11.23 CDKN2A EGFR
4 11.14 EGFR POT1
5 10.96 CDKN2A EGFR
6 10.84 CDKN2A EGFR MGMT
7 10.46 CDKN2A CDKN2C

GO Terms for Anaplastic Oligodendroglioma

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA repair GO:0045739 9.26 EGFR MGMT
2 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.16 CDKN2A CDKN2C
3 negative regulation of phosphorylation GO:0042326 8.96 CDKN2A CDKN2C
4 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.62 CDKN2A CDKN2C

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.13 CDKN2A CDKN2C EGFR
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2A CDKN2C

Sources for Anaplastic Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....